Deep Dives into Peptide Science
Research breakdowns, protocol design, and the latest findings from the world of peptide science. Written for researchers who care about the evidence.
A 10-Day Course of Nerve Growth Factor Eye Drops Was Followed for Four Years. It Did Not Prove a Lasting Effect.
A four-year follow-up found stable vision and MRI scans after an experimental 10-day NGF eye-drop trial. The result supports tolerability, not lasting efficacy.
Stopping Semaglutide Changed Glucose Control in Type 1 Diabetes. The Study Was Small.
A 12-week ADJUST-T1D extension found less time in range and greater glucose variability after semaglutide withdrawal. The signal matters, but the study included only 16 people who stopped treatment.
A Peptide PET Scan Detected Cardiac Amyloidosis With 94% Sensitivity. The Hard Part Comes Next.
A phase 3 trial found 124I-evuzamitide PET/CT detected cardiac amyloidosis with 94% sensitivity. Here is what the scan can—and cannot—prove.
An Oral Relaxin Mimic Changed Heart-Failure Hemodynamics. The Hard Endpoint Is Still Missing.
A 375-person phase 2b trial found that oral RXFP1 agonist AZD5462 changed heart-failure hemodynamics, but clinical benefit remains unproven.
GLP-1 Drugs Were Linked to Lower Mortality in Serious Mental Illness. This Is Not Yet Proof.
A 1.5-million-person study linked GLP-1 initiation to lower mortality and cardiovascular events in serious mental illness. The signal is strong, but it is still observational.
Mazdutide Cut Weight by 18.1% in a U.S. Trial. The 20% Dropout Rate Matters.
A new U.S. phase 2 trial found dose-dependent weight loss with mazdutide, but the strongest dose also produced a 20% adverse-event dropout rate.
Retatrutide Cut ApoB by 24%. That Is Not the Same as Preventing Heart Attacks
A new analysis found broad reductions in apoB, LDL particles, triglyceride-rich particles, and inflammation. The cardiovascular promise is real, but still rests on biomarkers.
VCT220 Cut Weight by 9.7% in 16 Weeks. The Titration Data Matter More Than the Pill
A 250-person phase II trial found up to 9.73% average weight loss in 16 weeks. The stronger lesson may be how sharply titration speed changed GI side effects.
A 2.5 mg Tirzepatide Dose Matched 5 mg in a New Study. It Does Not Rewrite the Label.
A prospective Japanese cohort found similar six-month weight loss on 2.5 mg and 5 mg tirzepatide. The result is intriguing, but it does not prove dose equivalence or change the US label.
Zenagamtide Worked as a Pill and a Weekly Injection. The Trade-Off Was Tolerability
Two Lancet phase 2 studies tested zenagamtide as a daily pill and weekly injection. Both lowered HbA1c, but high-dose tolerability complicates the headline.
Can Tirzepatide Spare More Muscle? Roche’s Emugrobart Trial Is About to Give Us a Clue
A 285-person phase 2 trial is testing tirzepatide with emugrobart, an anti-myostatin antibody. Here’s what it may reveal about fat loss, lean mass and the limits of the evidence.